QNX-10 is a fatty acid synthase (FASN) inhibitor with anticancer properties (IC50 = 0.7 μM). It exhibits potent FASN inhibition and cytotoxicity against colorectal and breast cancer cells. By upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-xL, QNX-10 induces apoptosis and causes cell cycle arrest at the S phase. This compound is utilized for investigating anticancer therapies targeting the FASN enzyme.

QNX-10, administered at concentrations ranging from 0-10 μM for 48 hours, exhibits cytotoxicity against HCT-116, Caco-2, and MCF-7 cells, with IC50 values of 1.5 μM, 2.1 μM, and 1.8 μM, respectively. It is non-toxic to HEK-293 cells, with an IC50 of 30.4 μM. QNX-10 (0.5-2.5 μM, 48 hours) inhibits cell cycle progression by inducing S-phase cell cycle arrest in HCT-116 cells. Additionally, QNX-10 (0.5-2.5 μM) shows dose-dependent apoptotic characteristics by increasing Bax and decreasing Bcl-xL and FASN levels in HCT-116 cells.